Journal of Stroke & Cerebrovascular Diseases
Volume 18, Issue 1 , Pages 56-59 , January 2009

Percent Change on the National Institutes of Health Stroke Scale: A Useful Acute Stroke Outcome Measure

  • Askiel Bruno, MD

      Affiliations

    • Department of Neurology, Indiana University School of Medicine, Indianapolis
    • Corresponding Author InformationAddress correspondence to Askiel Bruno, MD, Department of Neurology, Medical College of Georgia, 1120 15th Street, BI 3076, Augusta, GA 30912.
    • ,
  • Chandan Saha, PhD

      Affiliations

    • Department of Medicine, Division of Biostatistics, Indiana University School of Medicine, Indianapolis
    • ,
  • Linda S. Williams, MD

      Affiliations

    • Department of Neurology, Roudebush Department of Veterans Affairs Medical Center, Indianapolis

Received 2 September 2008 ,Accepted 11 September 2008.

References 

  1. Adams HP, Davis PH, Leira EC, et al. Baseline NIH stroke scale score strongly predicts outcome after stroke: A report of the trial of org 10172 in acute stroke treatment (TOAST). Neurology. 1999;53:126–131
  2. Broderick JP, Lu M, Kothari R, et al. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS TPA stroke trial. Stroke. 2000;31:2335–2341
  3. Young FB, Weir CJ, Lees KR. Comparison of the National Institutes of Health stroke scale with disability outcome measures in acute stroke trials. Stroke. 2005;36:2187–2192
  4. Bruno A, Saha C, Williams LS. Using change in the National Institutes of Health stroke scale to measure treatment effect in acute stroke trials. Stroke. 2006;37:920–921
  5. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–1587
  6. Publications Committee for the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, org 10172 (danaparoid), and outcome after acute ischemic stroke: A randomized controlled trial. JAMA. 1998;279:1265–1272
  7. Ingall TJ, O'Fallon WM, Asplund K, et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke. 2004;35:2418–2424
  8. Saver JL, Yafeh B. Confirmation of TPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-TPA stroke trials. Stroke. 2007;38:414–416
  9. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32–35

PII: S1052-3057(08)00182-1

doi: 10.1016/j.jstrokecerebrovasdis.2008.09.002

Journal of Stroke & Cerebrovascular Diseases
Volume 18, Issue 1 , Pages 56-59 , January 2009

Article Tools